Australia Genomics Market Size Projected to Reach USD 3.92 Billion during 2025-2033

The latest report by IMARC Group, “Australia Genomics Market Size, Share, Trends and Forecast by Component, Application, Technology, End-User, and Region, 2025-2033,” provides an in-depth analysis of the Australia genomics market. The report also includes competitor and regional analysis, along with a breakdown of segments within the industry. The Australia genomics market size reached USD 1.08 Billion in 2024 and is projected to grow to USD 3.92 Billion by 2033, exhibiting a CAGR of 13.80% during 2025-2033.

Report Attributes and Key Statistics:

Base Year 2024

Forecast Years 2025-2033

Historical Years 2019-2024

Market Size in 2024 USD 1.08 Billion

Market Forecast in 2033 USD 3.92 Billion

Market Growth Rate 2025-2033 13.80%

Australia Genomics Market Overview:

The Australia genomics market is witnessing rapid expansion as healthcare providers, research institutions, and government bodies are integrating genomics into mainstream medical practice. Stakeholders are investing in advanced sequencing technologies and AI-driven analytics, while the government is supporting national genomics programs and infrastructure upgrades. Efforts are being made to extend genomic services to regional and remote communities, aiming to ensure equitable access. These initiatives are fostering innovation, improving diagnostic accuracy, and enabling the development of personalized medicine, ultimately transforming the healthcare landscape across Australia.

Request For Sample Report: https://www.imarcgroup.com/australia-genomics-market/requestsample

Australia Genomics Market Trends and Drivers:

The market is seeing increasing adoption of AI-powered genomics platforms, which are accelerating the analysis of complex genetic data and supporting precision medicine. Strategic collaborations between research centers and clinical providers are driving the translation of research into clinical applications. The government’s investment in AI and genomics is facilitating the integration of genomic testing into routine healthcare, while the expansion of next-generation sequencing (NGS) technologies is making high-throughput, cost-effective testing more accessible. These trends are positioning Australia as a leader in genomic innovation and healthcare transformation.

Key drivers include the growing demand for personalized and precision medicine, significant government investment in genomics research and infrastructure, and advancements in sequencing and data analysis technologies. Increased public awareness of genetic testing benefits and nationwide efforts to embed genomics into standard care are accelerating market growth. Collaboration among federal and state health systems, research bodies, and clinical providers is also enhancing the accessibility and clinical relevance of genomics across Australia.

Australia Genomics Key Growth Drivers:

• Rising demand for personalized medicine

• Government investment in national genomics programs

• Advancements in sequencing and AI-driven technologies

• Increased awareness and acceptance of genetic testing

• Collaboration between research institutions and healthcare providers

Key Highlights of the Report:

• Comprehensive market size and forecast, 2024-2033

• Detailed segmentation by component, application, technology, end-user, and region

• In-depth analysis of technological trends and government initiatives

• Competitive landscape profiling major players and strategies

• Insights into the integration of genomics in routine healthcare

• Evaluation of regulatory, ethical, and data privacy considerations

Australia Genomics Market Segmentation:

Component Insights:

• Products

• Instruments and Software

• Consumables and Reagents

• Services

• Core Genomics Services

• NGS-Based Services

• Biomarker Translation Services

• Computational Services

• Others

Application Insights:

• Functional Genomics

• Epigenomics

• Biomarkers Discovery

• Pathway Analysis

• Others

Technology Insights:

• Sequencing

• Microarray

• Polymerase Chain Reaction

• Nucleic Acid Extraction and Purification

• Others

End-User Insights:

• Research Centers

• Hospitals and Clinics

• Pharmaceutical and Biotechnology Companies

• Others

Regional Insights:

• Australia Capital Territory & New South Wales

• Victoria & Tasmania

• Queensland

• Northern Territory & Southern Australia

• Western Australia

Competitive Landscape:

• Illumina Inc.

• Thermo Fisher Scientific Inc.

• Agilent Technologies Inc.

• Roche Holding AG

• Qiagen NV

• Bio-Rad Laboratories Inc.

• Danaher Corp

• Eppendorf

• Eurofins Scientific SE

• Myriad Genetics Inc.

• Oxford Nanopore Technologies PLC

• Pacific Biosciences of California Inc.

• Quest Diagnostics Inc.

• 23andMe Holding Co Class A

Australia Genomics Market News:

• June 2024: Australian Government invests A$57 million in AI and genomics research to boost diagnostic accuracy and accelerate precision medicine adoption.

• May 2025: Major public-private partnership announced to expand genomic testing infrastructure across regional Australia, aiming to reduce healthcare disparities.

Note: If you require specific information not currently within the scope of the report, we can provide it as part of the customization.

Ask an analyst for your customized sample: https://www.imarcgroup.com/request?type=report&id=34072&flag=C

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel. No.: (D) +91 120 433 0800

Americas: +1 631 791 1145